Faster access to new drugs doesn't always mean better treatment
- Written by Narcyz Ghinea, Doctoral Researcher, Centre for Values, Ethics and the Law in Medicine, University of Sydney
Weaker regulatory standards in the US can impact health everywhere.from shutterstock.comUS President Donald Trump recently chose an adviser to a large pharmaceutical company to lead the country’s drug regulation agency.
Scott Gottlieb – who reportedly sits on the boards of several small drug companies and is an adviser to...
